Search | Clinical Trials Finder

Conditions: Kidney Cancer
Interventions: Pazopanib, Temsirolimus, Quality of Life Assessment, Benadryl; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: End-Stage Renal Disease, Chronic Allograft Nephropathy
Interventions: Irbesartan, Pravastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Primary Total Hip Arthroplasty, Primary Total Knee Arthroplasty
Interventions: Diphenhydramine (Benadryl), Melatonin, Sleep Hygiene Education; Drug · Dietary Supplement · Behavioral
Lead sponsor: James A. Keeney; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
Interventions: Cetuximab, Questionnaire administration, Quality of life assessment; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pain
Interventions: Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 19
States / cities: Chandler, Arizona • Mesa, Arizona • Peoria, Arizona + 16 more

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Autism, Autism Spectrum Disorder
Interventions: Zolpidem, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: SARS-CoV-2 Infection
Interventions: Losartan, Placebo; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Healthy
Interventions: Tripelennamine, Diphenhydramine, Vehicle Control Cream Base; Drug
Lead sponsor: Palm Beach Atlantic University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Osteoarthritis, Knee
Interventions: Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin; Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 40 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: NAFLD
Interventions: Losartan; Drug
Lead sponsor: Miriam Vos, MD; Other
Eligibility: 11 Years to 19 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Suicide
Interventions: Ketamine; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Nausea, Vomiting
Interventions: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), Placebo, Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg); Drug
Lead sponsor: Joseph Hazelton; Industry
Eligibility: 18 Years and older
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Telmisartan, Standard of Care Regimen; Drug · Other
Lead sponsor: Tyler J Curiel; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Post-Traumatic Headache
Interventions: Metoclopramide, Diphenhydramine; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Blood Cancer, Multiple Myeloma
Interventions: Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF); Procedure · Drug · Radiation
Lead sponsor: Wen-Kai Weng; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
Interventions: Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more

Search by objective public record fields.

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Prevention of Kidney Transplant Rejection

Total Joint Arthroplasty and Sleep

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Safety Trial of Naproxen Sodium/ Diphenhydramine

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Trial of Zolpidem for Sleep in Children With Autism

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Study of Losartan in the Treatment of NAFLD in Children

Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Telmisartan in Prostate Cancer

Metoclopramide for Post-Traumatic Headache. A Pilot Study

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

HALT Progression of Polycystic Kidney Disease Study A

Allo HSCT Using RIC for Hematological Diseases

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)